229 related articles for article (PubMed ID: 12031965)
41. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
[TBL] [Abstract][Full Text] [Related]
42. α-1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction.
Wang J; Sun Z; Gou W; Adams DB; Cui W; Morgan KA; Strange C; Wang H
Diabetes; 2017 Apr; 66(4):970-980. PubMed ID: 28069642
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
[TBL] [Abstract][Full Text] [Related]
44. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
45. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Scherstén F; Wahlund G; Björnheden T; Carlsson S; Mattsson C; Grip L
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):235-41. PubMed ID: 12695745
[TBL] [Abstract][Full Text] [Related]
46. Regulation of Instant Blood Mediated Inflammatory Reaction (IBMIR) in Pancreatic Islet Xeno-Transplantation: Points for Therapeutic Interventions.
Kourtzelis I; Magnusson PU; Kotlabova K; Lambris JD; Chavakis T
Adv Exp Med Biol; 2015; 865():171-88. PubMed ID: 26306450
[TBL] [Abstract][Full Text] [Related]
47. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation.
Moberg L; Johansson H; Lukinius A; Berne C; Foss A; Källen R; Østraat Ø; Salmela K; Tibell A; Tufveson G; Elgue G; Nilsson Ekdahl K; Korsgren O; Nilsson B
Lancet; 2002 Dec 21-28; 360(9350):2039-45. PubMed ID: 12504401
[TBL] [Abstract][Full Text] [Related]
48. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Klement P; Carlsson S; Rak J; Liao P; Vlasin M; Stafford A; Johnston M; Weitz JI
J Thromb Haemost; 2003 Mar; 1(3):587-94. PubMed ID: 12871470
[TBL] [Abstract][Full Text] [Related]
49. Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Eriksson M; Saldeen T; Mattsson C; Larsson A
Acta Anaesthesiol Scand; 2000 Jan; 44(1):24-31. PubMed ID: 10669267
[TBL] [Abstract][Full Text] [Related]
50. Characterization of Innate Immunity in an Extended Whole Blood Model of Human Islet Allotransplantation.
Hårdstedt M; Lindblom S; Karlsson-Parra A; Nilsson B; Korsgren O
Cell Transplant; 2016; 25(3):503-15. PubMed ID: 26084381
[TBL] [Abstract][Full Text] [Related]
51. Thrombin-activatable fibrinolysis inhibitor is activated in an instant blood-mediated inflammatory reaction after intraportal islet transplant.
Wang S; Zhao Z; Cong Z; Suo G
Exp Clin Transplant; 2014 Feb; 12(1):62-6. PubMed ID: 24188431
[TBL] [Abstract][Full Text] [Related]
52. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation.
Johansson H; Lukinius A; Moberg L; Lundgren T; Berne C; Foss A; Felldin M; Källen R; Salmela K; Tibell A; Tufveson G; Ekdahl KN; Elgue G; Korsgren O; Nilsson B
Diabetes; 2005 Jun; 54(6):1755-62. PubMed ID: 15919797
[TBL] [Abstract][Full Text] [Related]
53. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
54. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Hellgren M; Johansson S; Eriksson UG; Wåhlander K
BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
[TBL] [Abstract][Full Text] [Related]
55. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Fager G; Cullberg M; Eriksson-Lepkowska M; Frison L; Eriksson UG
Eur J Clin Pharmacol; 2003 Aug; 59(4):283-9. PubMed ID: 12845508
[TBL] [Abstract][Full Text] [Related]
57. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies.
van der Windt DJ; Bottino R; Casu A; Campanile N; Cooper DK
Xenotransplantation; 2007 Jul; 14(4):288-97. PubMed ID: 17669170
[TBL] [Abstract][Full Text] [Related]
58. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Eriksson M; Larsson A; Saldeen T; Mattsson C
Thromb Haemost; 1998 Dec; 80(6):1022-6. PubMed ID: 9869178
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
[TBL] [Abstract][Full Text] [Related]
60. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
